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Abstract
Recently,wecharacterizedtumorsuppressorcandidate5(Tusc5)asanadipocyte-neuronPPARgtargetgene.Ourobjective
herein was to identify additional genes that display distinctly high expression in fat and neurons, because such a pattern
could signal previously uncharacterized functional pathways shared in these disparate tissues. g-Synuclein, a marker of
peripheralandselectcentralnervoussystemneurons,wasstronglyexpressedinwhiteadiposetissue(WAT)andperipheral
nervous system ganglia using bioinformatics and quantitative PCR approaches. g-Synuclein expression was determined
during adipogenesis and in subcutaneous (SC) and visceral adipose tissue (VAT) from obese and nonobese humans.
g-Synuclein mRNA increased from trace levels in preadipocytes to high levels in mature 3T3-L1 adipocytes and decreased
;50% following treatment with the PPARg agonist GW1929 (P , 0.01). Because g-synuclein limits growth arrest and is
implicated in cancer progression in nonadipocytes, we suspected that expression would be increased in situations where
WAT plasticity/adipocyte turnover are engaged. Consistent with this postulate, human WAT g-synuclein mRNA levels
consistently increased in obesity and were higher in SC than in VAT; i.e. they increased ;1.7-fold in obese Pima Indian
adipocytes (P ¼ 0.003) and ;2-fold in SC and VAT of other obese cohorts relative to nonobese subjects. Expression
correlated with leptin transcript levels in human SC and VAT (r ¼ 0.887; P , 0.0001; n ¼ 44). g-Synuclein protein was
observed in rodent and human WAT but not in negative control liver. These results are consistent with the hypothesis that
g-synuclein plays an important role in adipocyte physiology. J. Nutr. 138: 841–848, 2008.
Introduction
Identifying the subcellular and systemic networks that connect
energy balance, tissue fuel utilization patterns, and body com-
position will be an important step toward understanding how
metabolic homeostasis and healthy body weight are regulated.
Theremarkablemolecularandphysiologicalshiftsthattakeplace
in response to changes in ambient temperature in rodents can
be leveraged to identify genes and pathways that participate in
these networks. Through transcriptome analysis of temperature-
dependentgeneexpressionchangesinthermogenicmousebrown
adipose tissue (BAT),
14 we previously characterized a cold-
repressed white adipose tissue (WAT) and BAT gene (1) termed
tumor suppressor candidate 5 (Tusc5). Rat Tusc5 has been
identiﬁed as a BAT and WAT gene downregulated by cold ex-
posure and induced during brown adipocyte maturation (2,3).
Based on the presence of a CD225 cell growth-regulating protein
domain, upregulation of expression by a PPARg agonist, and
induction of the gene following exit from the mitotic clonal
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model in which white adipocyte Tusc5 activities are associated
withentryintoorpersistenceofthefullymature,growth-arrested
metabolic and structural phenotype of adipocytes (1). Identiﬁca-
tion of Tusc5 and other adipocyte candidates that modulate cell
growth is important to understand mechanisms that underlie
adipose malleability (plasticity) characterized by phenotypic
change, cell type conversion (brown-like/white-like fat cell
transdifferentiation), and/or adipocyte turnover [see, e.g. (4,5)
for reviews].
Like adipocytes, nerves associated with the somatosensory
system and peripheral nerves in general display functional and
morphological plasticity in response to external stimuli, inﬂam-
mation, and neuronal damage (6–8). Interestingly, in addition to
adipocytes, Tusc5 mRNA and protein are expressed at high
amounts in peripheral afferent nerves that convey ambient
temperature, peripheral tissue status, and other information to
the brain (1). The physiological implications of robust coex-
pression of select proteins in adipocytes and peripheral nervous
system (PNS) neurons remain to be elucidated, but these factors
may provide a link connecting peripheral and environmental
cues, tissue malleability, and metabolism. Identiﬁcation of addi-
tional genes coexpressed in peripheral nerves and adipocytes
could illuminate previously underappreciated functional aspects
shared between these disparate tissues. To this end, mining of
murine gene tissue expression patterns in the SymAtlas database
(9) led to the novel ﬁnding that g-synuclein, a well-established
peripheral neuron marker also expressed in several central
nervous system (CNS) sites (10–14) and implicated in cancer
progression and cell survival (15), is strongly expressed in adi-
pocytes. Considering its putative involvement with cancer cell
progression, we hypothesized that adipocyte g-synuclein would
be downregulated in fat by PPARg agonism and upregulated in
obesity, because development of the latter involves WAT plastic-
ity and PPARg is critical for promoting growth arrest/terminal
differentiation following the mitotic clonal expansion phase of
newly differentiated fat cells. Results using PPARg agonists in
3T3-L1 adipocytes and a survey of expression in WAT derived
fromnonobeseandobesehumancohortssupporttheseconcepts.
Ourﬁndingsareconsistentwiththehypothesisthatg-synucleinis
aPP ARg targetgenewithanimportantroleinfatcellphysiology.
Methods
3T3-L1 adipocyte differentiation and PPARg agonist studies. The
changes in g-synuclein mRNA expression during the course of fat cell
differentiation and maturation and following agonism of PPARg were
tested in the 3T3-L1 adipogenesis model. Results herein were generated
using the samples described in our recently published studies and details
regardingcellcultureconditionsmaybefoundinthatreport(1).Proof-of-
principle studies tested the ability of the potent non-thiazoladinedione
(TZD) PPARg agonist GW1929 (16) to regulate g-synuclein gene
expression at various points in the 3T3-L1 adipocyte differentiation and
maturation process, as indicated. For these experiments, cells were
cultured for the times and doses indicated in media containing vehicle
(dimethyl sulfoxide; 0.1% by volume) or GW1929 (0.1% by volume).
RNAwaspreparedfrom3T3-L1adipocytesusingTRIzol-basedmethods
for cell culture samples (Ambion). We checked RNA abundance and
integrity using a NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies)andanAgilent2100bioanalyzer(Agilent),respectively,per
the manufacturer’s instructions.
Human WAT mRNA. The effect of obesity and weight loss and differ-
encesbetweenadiposedepotswithrespecttog-synucleingeneexpression
wereanalyzedusingarchivedhumanWATsamples.Sampleswerederived
from female volunteers undergoing surgery or were obtained via sub-
cutaneous (SC) biopsy before and after a very low energy weight loss
regimen, as previously described (17–19). Brieﬂy, for comparisons
between lean and obese SC WAT and visceral adipose tissue (VAT;
omental), samples from experiments described by M. Grino et al. (19)
derived from 10 nonobese and 12 obese (BMI 37.9 6 1.5 kg/m
2) women
were studied. VAT was collected in the course of laparoscopy or
laparotomy for gastroplasty or gynecological procedures and SC fat
was obtained in parallel from the abdominal region. mRNA prepared
from these samples was transferred to the Western Human Nutrition
Research Center for quantitative PCR analyses. WAT mRNA samples
were also obtained by K. Cle ´ment et al. from a subset (n ¼ 21) of the
morbidlyobeseadult womendescribedbyCancelloet al. (18) and results
from those samples were compared with nonobese control samples (n ¼
9).MatchedSCandomentalVATmRNAsampleswereavailablefrom20
of the obese subjects and tested to compare depot-speciﬁc gene expres-
sion. In another group of adult French obese women, SC biopsy before
andafteraverylowenergydiet(VLED)(17)enabledtestingoftheeffects
of weight loss on gene expression. Brieﬂy, 12 obese women participating
in the VLED reduced their daily energy intake by one-third (by 3940 6
113kJ/dwith35%protein,20%lipids,and45%carbohydrates)for21d.
None of the subjects had a familial or personal history of diabetes or was
takingmedicationsandpriortothestudy,allvolunteerswereattheirpeak
weightandwerenotonarestrictivediet.Subjectswerenotinvolvedinan
exercise program. Abdominal SC fat specimens (;1 g) from the peri-
umbelical region were obtained by needle aspiration under local
anesthesiaafteranovernightfastbeforeandafterthedietaryintervention
inobesesubjectsandinnonobesevolunteers(n¼7)usedforcomparison.
All biopsies were washed in PBS and stored in RNALater preservative
solution(Qiagen)at280 Cuntilanalysis.TotalRNAwasextractedusing
the RNeasy total RNA Mini kit (Qiagen) and quantitative real-time PCR
(TaqMan) using ABI primers and probes described below was performed
bythe INSERMU872laboratory. ForhumanWAT Western blotanalysis
(see below), a sample of SC WAT was obtained from the upper gluteal
regionofanadultfemalevolunteervianeedlebiopsyunderlocallidocaine
anesthesia. The sample was washed twice in cold PBS to clean the biopsy
of bloodandloose connectivetissueandwasﬂash-frozenpriorto storage
at 280 C. Clinical investigations were approved by the ethical commit-
tees of each participating center and were performed according to the
Declaration of Helsinki.
Gene expression analyses. RNA abundance of g-synuclein and other
genes of interest were measured using quantitative real-time PCR. These
assays utilized gene-speciﬁc TaqMan primers and FAM-MGB labeled
probes (Assays-on-Demand, Applied Biosystems) and were analyzed in
duplicate or triplicate for each sample using an ABI 7900HTinstrument.
Primers/probe ABI identiﬁers for human reagents were g-synuclein
(Hs00268306_m1), leptin (Hs00174877_m1), and 11b-hydroxysteroid
dehydrogenase (Hs00194153_m1), and for mouse, g-synuclein
(Mm00488345_m1) and others described previously (1). Mouse and
human tissue panel samples and samples derived from nonobese and
obese WAT (19) were assayed using a 2-step process with preparation of
cDNA from total RNA followed by quantitative real-time PCR. Brieﬂy,
for each sample, cDNA was prepared from 1–5 mg of total RNA using
Superscript III reverse transcriptase (Invitrogen) followed by RNase-H
treatmentperthemanufacturer’sinstructions.Reactionswerecarriedout
in a 384-well format and contained the following in each well: cDNA
correspondingto40ng(tissuepanels)or2ng(obeseandleanhumanWAT
samples) of original total RNA, 13 master mix (ABI Universal PCR
Master Mix, part no. 4304437), and 13 primer-probe mix (pilot studies
examiningtherangeoflinearitybetweenPCRcyclenumberandtemplate
amount in human WAT samples revealed that as little as 2 ng per well
could be used for g-synuclein, leptin, and 18S cDNAs). Cycle conditions
were 95 C for 10 min, then 45 cycles of 95 C for 15 s/60 C for 1 min.
Ampliﬁcation cycle number (Ct) of 18S for each sample was determined
using commercial 18S primers and probe (ABI) to correct for template
loading differences across all target genes (DCt method: DCt ¼ sample
Ct 2 18S Ct), and expression values were determined relative to control
transcript levels using a mathematical formula as previously described
(1).
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blot analyses of g-synuclein protein in murine, rat, and human WAT
samples were conducted using an anti-g-synuclein antibody E-20 (Santa
Cruz Biotechnology). Brieﬂy, tissue samples were homogenized using
MPER extraction reagent (Pierce) with HALT protease and phosphatase
inhibitors (Pierce). Protein concentrations were quantitated using the
bicinchoninic acid assay (Pierce). Forty micrograms of total protein
was separated on a 12% Bis-Tris SDS gel (Invitrogen) using 2-(N-
morpholino)ethanesulfonic acid running buffer (Invitrogen). The pro-
teins were transferred to polyvinylidene diﬂuoride membrane and
immunoblotted with goat anti-g-synuclein antibody (1:100) in PBST
overnight. Speciﬁc signal was detected with a horseradish peroxidase-
conjugatedsecondaryantibody(1:10,000donkeyanti-goatHRP,sc-2020,
Santa Cruz Biotechnology) using Visualizer ECL reagent (Millipore).
Blots wereimagedusing a Fluorochem 8800instrument (AlphaInnotech).
Samples of liver, retroperitoneal WAT, epididymal WAT, and SC WAT
(inguinal region) for Western blot studies were obtained from 3 male
B6D2F1 mice fed a high-fat diet (60% of energy from fat; D12492,
Research Diets) for 8 wk. Twelve-week-old Zucker rats used for WAT
harvest were fed a puriﬁed diet composed of (g/kg): casein (210),
methionine (3), cornstarch (200), corn oil (80), vitamin mix (15), min-
eral mix (60), cellulose(392), and alphacel(40). Rats were food deprived
;4–6 h prior to tissue harvest, killed with CO2, and tissues were ﬂash-
frozen prior to storage at 280 C. For immunohistochemistry (IHC) of
murine fat tissue, dissected SC WAT from a 6-mo-old C57BL/6 female
mouse was ﬁxed, parafﬁn embedded, and sectioned as described pre-
viously (13). Afﬁnity puriﬁed SK32 rabbit polyclonal anti-g-synuclein
antibody (11) in a 1:50 dilution and Vecstain Elite detection kit (Vector
Laboratories) were used for immunohistochemical detection of g-synuclein
on these sections. To demonstrate speciﬁcity of immunostaining, 1 mL
of diluted SK23 antibody was preincubated with 10 mg of a synthetic
15-mer C-terminal peptide of mouse g-synuclein that was used as an
immunogen for production of this antibody. All animal studies were
conducted under protocols adhering to Animal Welfare Act Guidelines,
approved by the Animal Care and Use Committees at UC, Davis (for
Western blot samples) and Cardiff University (IHC study).
Materials. Insulin, dexamethasone, 3-isobutyl-1-methylxanthine, and
GW1929 were purchased from Sigma, DMEM and fetal bovine serum
from Gibco/BRL (Invitrogen), and cell culture plates were purchased
from Nunc. Murine and human total RNA tissue panels were obtained
from Clontech and human preadipocyte (stromal-vascular cells from
WAT biopsy) and cultured and fresh adipocyte total mRNAs were
bought from Zenbio. Mouse epididymal WAT used in the mRNA tissue
panel was from pooled adult C57BL/6J tissues.
Statistics. Changes in gene expression over time with and without
PPARg activation during 3T3-L1 adipogenesis were evaluated using a
2-wayANOVAtestingforsigniﬁcanteffectsoftime,treatment,andtime3
treatment (Prism 4.03 software; GraphPad). A similar approach was
used to evaluate effects of obesity, WAT depot, and obesity 3 depot
interactions, or to test obesity, sex, and obesity 3 sex interactions as
relevant in human studies. When interactions were signiﬁcant, post-hoc
Bonferroni tests were employed to test for treatment effects within
groups. Comparisons between 2 groups were done using a Student’s t
test. Dose-response data were tested by 1-way ANOVA with a post hoc
Dunnett’s test comparing groups to the vehicle-treated control. The
relationship between g-synuclein and leptin mRNA abundance was
evaluated by Pearson correlation statistic (Prism 4.03). Means 6 SEM
are presented and differences were considered signiﬁcant at P , 0.05.
Results
Tissue expression proﬁle of g-synuclein. Mouse gene chip
tissue expression surveys cataloged in SymAtlas, a public data-
base constructed by the Genomics Institute of the Novartis
Research Foundation (9), were queried to identify genes dis-
playing predominant expression in somatosensory nervous sys-
tem ganglia [dorsal root ganglia (DRG) and trigeminal ganglia],
WAT, and/or BAT. g-Synuclein, a marker of peripheral neurons
and select CNS neurons (10,11,13,14), emerged as 1 of 2 genes
ﬁtting this pattern (Supplemental Table 1); the other identiﬁed
gene was Tusc5. High expression of the gene in murine WATwas
conﬁrmed by real-time quantitative PCR, whereas g-synuclein
mRNA was found to be negligible in other tissues tested
(SupplementalFig.1).Inhumans,g-synucleinmRNAabundance
was highest in the DRG and mRNA prepared from isolated SC
adipocytes, with trace to negligible g-synuclein mRNA in most
other tissues (including preadipocytes) with the exception of
spinal cord, brain, cerebellum, and adrenals where levels were
;36, 43, 33, and 42% of adipocytes, respectively (Supplemental
Fig. 1). g-Synuclein protein was readily detected by Western blot
analysis in murine and human WAT samples but not in negative
control mouse liver (Fig. 1A); g-synuclein protein was also
observedinretroperitonealWATandDRG,butnotliversamples,
derivedfrom12-wk-oldfemale Zuckerrats(datanotshown;n¼
2). Consistent with our observation that g-synuclein mRNA
resides in adipocytes in humans (Supplemental Fig. 1; see Results
below for Pima Indian SC adipocytes), g-synuclein protein
appears to be located in mouse adipocytes as judged by strong
IHC staining patterns(Fig. 1B)that were well abovebackground
(Fig. 1C).
g-Synuclein mRNA expression patterns in differentiating
3T3-L1 adipocytes. Determining the time frame over which
g-synuclein is expressed during the 3T3-L1 adipocyte differen-
tiation and maturation program will be useful to understand
when g-synuclein function affects fat cell physiology. We have
FIGURE 1 g-Synuclein protein expression in adipose tissue. (A)
Western blot revealed g-synuclein protein expression in mouse WAT,
BAT, and human SC WAT and no detectable expression in murine liver
negative control. Mouse adipose depots: RP, Retroperitoneal; SC,
inguinal SC; Epi, epididymal; BAT, intrascapular BAT. Two additional
mice were assayed and displayed a qualitatively similar pattern of
g-synuclein protein in SC, RP, and BAT depots; however, epididymal
WAT g-synuclein protein level was highly variable across animals (data
not shown). (B,C) Immunohistochemical evidence for g-synuclein
protein expression in murine adipocytes. Paraffin sections (8 mm) of
the SC WAT from a 1-mo-old C57BL/6 female mouse was stained with
anti-g-synuclein SK23 antibody (B) or the same antibody preincubated
withanexcessofimmunizationpeptide(C)asdescribedin‘‘Methods.’’
A similar block of immunostaining was achieved by preincubation of
antibody with recombinant mouse g-synuclein (data not shown).
g-Synuclein is an adipocyte-neuron gene 843previously outlined gene expression clusters in this system for
Tusc5 and 24 other adipocyte differentiation and functional
markers and found that the pattern of Tusc5 expression
clustered with a group of metabolically relevant mature adipo-
cyte markers (1). g-Synuclein mRNA expression was assayed
using the samples from those experiments and had a pattern
consistent with that observed for a gene cluster that included
Tusc5, phosphoenolpyruvate carboxykinase 1, leptin, adipsin,
and glucose transporter (GLUT) 4 (Fig. 2). This suggests that
these factors share gene regulatory elements.
Effects of the PPARg agonist GW1929 on expression
proﬁles in 3T3-L1 adipocytes. Many metabolically relevant
adipocyte genes are regulated by PPARg activities and PPARg
actions promote entry of developing fat cells into the growth-
arrested mature adipocyte phenotype. Thus, should g-synuclein
activity be important to adipocyte development and/or metab-
olism, it is reasonable to consider that the gene would be
responsive to PPARg agonism. In proof-of-concept studies,
g-synuclein mRNAwas measured in fully differentiated 3T3-L1
adipocytes treated for 18 h with the potent non-TZD GW1929,
provided at a concentration just above those reported to
stimulate in vitro adipocyte glucose uptake and GLUT1 expres-
sion (20) and lipogenesis in C3H10T1/2 cells (16) and at lower
concentrations to establish a dose response. In response to short-
term GW1929, g-synuclein mRNA abundance decreased by up
to ;50% (Fig. 3). This pattern was paralleled qualitatively by
that of leptin mRNA (Fig. 3), consistent with the notion that
g-synuclein and leptin could share gene regulatory elements
that confer repression following PPARg activation in fat cells.
g-Synuclein and leptin mRNA levels were also decreased by the
less potent thiazolidinedione troglitazone, but the effective doses
required were at least 5 times higher compared with GW1929
(data not shown). In separate studies, the ability of a single dose
of GW1929 to decrease g-synuclein expression following short-
term (18 h) exposure to the compound was most apparent in
mature fat cells, in contrast to preadipocytes and immature
adipocytes in which g-synuclein mRNA modestly increased,
similar to what was observed for leptin (Supplemental Fig. 2).
Effects of human obesity and WAT depot site on
g-synuclein mRNA expression. g-Synuclein has been impli-
cated as a cancer marker and might be involved in cell survival
mechanisms based on its overexpression in some cancers and
studies examining cell death upon titration of g-synuclein ex-
pression in vitro (see ‘‘Discussion’’). Thus, we reasoned that in
obesity,WATg-synucleinexpressionandactivitywouldincrease,
because this condition, atleast at somestages of its development,
is characterized by increased adipocyte proliferation and, poten-
tially, enhanced adipocyte plasticity/turnover to adapt to a high
energy load. Consistent with this hypothesis, WAT g-synuclein
transcript levels signiﬁcantly increased in obesity in several
independent groups of human subjects. The pattern was initially
revealed when the National Center for Biotechnology Informa-
tion Gene Expression Omnibus (GEO) gene chip database was
queriedtoidentifystudiesinwhichg-synucleinwasdifferentially
expressed in obesity. The g-synuclein mRNA level was upregu-
lated in isolated SC adipocytes derived from obese nondiabetic
adult Pima Indians compared with nonobese, nondiabetic Pima
Indians [GEO accession no. GSE2508, derived from studies by
Permana et al. (21)]. Follow-up analysis using the gene chip raw
data from male and female subjects conﬁrmed that WAT
g-synuclein mRNA levels increased in obesity (P , 0.01), an
outcome that is largely inﬂuenced by differences between obese
and nonobese males (P , 0.05, obesity 3 sex interaction); signal
intensities were 44,817 6 2142 in obese males and 29,629 6
3927 in nonobese males, respectively (P , 0.01). Signal inten-
sitiesdidnotdifferbetweenobese(38,02161549)andnonobese
(35,770 6 2474) females. Consistent with our quantitative
RT-PCR human tissue expression proﬁle (SupplementalFig. 1),a
GEOqueryofa2ndPimaIndianmicroarraystudyindicatedtrace
tonoexpressionofg-synucleininculturedpreadipocytes/stromal
vascular cells (GEO accession no. GSE2510).
We next examined WAT mRNA samples from a cohort of
obese and nonobese French women previously described in an
expression proﬁle study of adipose 11b-hydroxysteroid dehy-
FIGURE 2 Transcript levels of a suite of differentiation stage and
functional markers were determined by quantitative real-time PCR in
3T3-L1 cells at various times before and after initiation of the adipocyte
differentiation program. Results for phosphoenolpyruvate carboxyki-
nase 1 (PEPCK1), GLUT4, leptin, adipsin, and Tusc5 [adapted with
permission from (1)] are shown for comparison. Differentiation of 2 d
confluent 3T3-L1 fibroblasts was triggered at d 0 by 48 h exposure to
differentiation medium. Transcript levels for each gene are expressed
relativetothemeanforthatgeneond14postdifferentiation.Valuesare
means6SEM,n¼3(someerrorbarsarewithinthesymbol).Theeffect
of time was significant for all genes, P , 0.0001.
FIGURE 3 Reductionofg-synucleinandleptinmRNAlevelsbyshort-
term treatment with the PPARg agonist GW1929 in mature 3T3-L1
adipocytes. RNA from mature (12 d differentiated) 3T3-L1 adipocytes
was isolated from cells exposed to various doses of the non-TZD
GW1929 and relative transcript abundances measured by quantitative
real-timePCR.Valuesaremeans6SEM,n¼4perdose.Transcriptlevel
in vehicle-treated cells was considered 1.0, P , 0.001, 1-way ANOVA;
**P , 0.01, significantly different vs. 0 dose control expression.
844 Oort et al.drogenase that demonstrated signiﬁcantly increased expression
of the latter in obesity (19). g-Synuclein mRNA abundance
signiﬁcantlyincreasedintheSCandVATofobesecomparedwith
nonobese women (Fig. 4A), a pattern also observed for leptin
(Fig. 4B). Visceral fat g-synuclein transcript levels were signiﬁ-
cantly lower compared with SC in both nonobese and obese
groups. Visual inspection of the raw data for g-synuclein and
leptinexpressioninall44samples(nonobeseandobese,VAT,and
SC) suggested coordinate expression of leptin and g-synuclein
and this was conﬁrmed through correlation analysis that indi-
cated a correlation between expression of these genes (r ¼ 0.887;
P,0.0001),regardlessofsamplesource(Fig.5).Theabundance
of g-synuclein mRNA was next assayed in SC WAT samples
derived from a different cohort of obese and nonobese French
women. Consistent with the results discussed above, expression
signiﬁcantly increased in obese SC WAT, with a qualitatively
similar pattern for leptin mRNA (Fig. 6A). Also consistent was
the ﬁnding that g-synuclein and leptin mRNA levels were sig-
niﬁcantly lower in VATrelative to SC WATin obese women (Fig.
6B). In a study examining the effect of a weight loss regimen in
obese women, g-synuclein mRNA levels were initially higher in
obeseSCWATvs.nonobesecontrols(202626%vs.100638%
of nonobese expression, respectively; P , 0.05), and were reduced following the VLED intervention (131 6 18% of
nonobese controls; P . 0.05).
Discussion
PNS functions profoundly inﬂuence metabolic homeostasis.
Somatosensory circuits, for instance, transmit environmental
and tissue temperature information to the brain, thus enabling
ﬁne-tuning of downstream thermoregulatory and food intake
responses emanating from the CNS. The recent body of work by
Bartness et al. [see reviews (22,23)] has shown that partial
chemical ablation of somatosensory afferents in WAT increases
the size of select WAT depots in rats, indicating that the
somatosensory system transmits information related to adipos-
ity to the CNS, which in turn provides efferent signals that
inﬂuence depot growth. Interestingly, sensory nerves have also
been implicated in cold-related brown adipocyte development in
WAT depots (24) and may modulate BAT thermogenic responses
to norepinephrine (25,26). The sympathetic nervous system also
regulates adipose function via lipolytic signaling and through
modulation of proliferative events in WAT (27,28) and BAT
(29,30). More recently, Yamada et al. (31) demonstrated that
afferent signals from murine WAT helped control leptin sensi-
tivity and food intake phenotypes. Our discoveries of Tusc5 (1)
and g-synuclein (this study) as proteins most strongly expressed
in PNS neurons and adipocytes addto this body of knowledge by
illustrating that in addition to anatomical connectivity between
the PNS and WAT, there are apparently certain functional
pathways shared by these otherwise disparate systems. To our
knowledge, an association between g-synuclein activities and
metabolism, obesity, or fat cell physiology has not been reported
previously.
g-Synuclein mRNA expression was induced as 3T3-L1 adi-
pocytes developed into mature fat cells in culture and mRNA
levels for this gene were high in isolated human SC adipocytes,
suggesting an important function primarily in maturing-to-
mature adipocytes. However, the role of g-synuclein in adipo-
cytes remains to be elucidated. One possible function could be
participation in events associated with exit from the growth-
arrested,terminally differentiatedmaturefatcell phenotypeand/
or support of adipocyte cell survival. Support for these views
comes from the oncology literature [see (15) and refs. therein].
FIGURE 5 Human adipose tissue g-synuclein mRNA levels are
correlated with leptin mRNA levels. Utilizing the individual sample data
used to generate results depicted in Figure 4 (SC and VAT from obese
and nonobese women, n ¼ 44 samples), the relationship between
g-synuclein and leptin mRNA abundance was evaluated by correlation
analysis (Pearson correlation).
FIGURE 4 g-Synuclein transcript level is highest in SC adipose
tissue and significantly increased in obesity, a pattern similar to leptin,
in adult women. Samples from a cohort of obese (n ¼ 12) and
nonobese (n ¼ 10) adult women (19) were used to assay mRNA
abundance for g-synuclein (A) and leptin (B) by quantitative RT-PCR.
Values are means 6 SEM with the nonobese SC mRNA level for each
gene considered 100%. Obesity (P , 0.0001), fat depot (P , 0.0001),
and their interaction (P , 0.05) affected both genes. Means without a
common letter differ, g-synuclein (SNCG): P , 0.05, a vs. b; P ,
0.001, c vs. a,b. Leptin: P , 0.0001, a vs. b; P , 0.001 c vs. a,b.
g-Synuclein is an adipocyte-neuron gene 845Thesestudieshighlightthatdespitelowtonondetectablelevelsin
most normal tissues, g-synuclein is overexpressed in several
hyperplastic tissues, including ovarian cancer and advanced
breast cancer tissue. Furthermore, ectopic overexpression of
g-synuclein in breast cancer lines and experimental knockdown
of g-synuclein in the T47D breast cancer cell line led to increased
and decreased cell growth, respectively. Our preliminary results
using siRNA knockdown of g-synuclein in several breast cancer
cell lines (Supplemental Fig. 3) are consistent with these results.
As reviewed by Ahmad et al. (15), the effect of g-synuclein to
promote cancer cell proliferation or cell survival is reportedly via
actionsthatreducetheactivitiesofmitoticgrowtharrestproteins
and enhance cell cycle progression. There is evidence that
g-synuclein activates MAP kinase as part of its pro-proliferation
activities and induces several matrix metalloproteinases that
support cell migration and metastasis [see (15)].
Should tissue plasticity and cell survival properties of
g-synuclein manifest in adipocytes, it is anticipated that the pro-
tein plays a role in regulating such events as net fat cell turnover,
transdifferentiation, and/or exit from the fully differentiated,
mature fat cell phenotype. There is growing support that WAT is
malleable, or plastic, in terms of its component adipocyte
phenotypes and fat cell numbers [see reviews by (4,5)]. The
positive energy balance associated with obesity development, for
instance, leads to increased adipocyte size coupled to an expan-
sion of adipocyte numbers to accommodate the larger energy
load. Phenotypic and morphological conversions (transdiffer-
entiation events) in subpopulations of adipose cells enable these
cells to acquire white adipocyte- or brown adipocyte-like
characteristics, even without proliferation from preadipocyte
precursors per se. Some have suggested that mature, fully
differentiated adipocytes can ‘‘de-differentiate’’ such that these
cells revert phenotypically to resemble adipocytes derived from
earlier stages of the adipogenic program (32–35) and/or acquire
proliferative potential (35). We have consistently observed
increased adipose expression of g-synuclein mRNA in obese
humansubjects, which hypotheticallymay signal increased WAT
plasticity or engagement of antiapoptotic pathways in fat cells as
adaptational responses to a chronically high energy storage load.
WAT g-synuclein mRNAexpression wasreduced following3 wk
of weight loss in our obese subjects, a period in which energy
storage is reduced and WAT energy stores are mobilized.
Furthermore, it is interesting that g-synuclein expression was
consistently higher in SC fat than in internal VATand the former
is typically considered to manifest a greater phenotypic and
morphologic plasticity, i.e. in response to TZD. Additional
studies are required to assess whether observed differences in
transcript abundance in obesity and following dieting also occur
the protein level, but it is notable that we have readily detected
g-synuclein protein in WAT from multiple species.
Treatment with antidiabetic TZD drugs leads to profound
changes in WAT, including an increased prevalence of small- to
medium-sized adipocytes, higher numbers of apoptotic adipo-
cytes, changes indicative of increased metabolism including
emergence of brown adipocyte-like cells in WAT depots, and
enhanced insulin sensitivity (36–39). Our ﬁnding that short-term
treatment with the PPARg agonists GW1929 and troglitazone
signiﬁcantly reduced g-synuclein mRNA levels in differentiated
adipocytes raises the interesting possibility that WAT changes
after in vivo TZD treatment might involve regulation of adipo-
cyte g-synuclein expression, an idea that awaits experimental
validation.Notably,usinganalgorithmtopredictPPARresponse
elements across the human genome, the g-synuclein gene was
identiﬁed as containing this regulatory motif [see supplemental
tables in (40)].
In addition to a putative role in cell survival and cell cycle
regulation, our results and information from the literature sug-
gest that other functions for g-synuclein are possible, including
chaperone activities for secreted and nonsecreted proteins [i.e.
(41–44) and refs. therein] and involvement with metabolically
relevant events in the cell. With respect to the latter, we have
observed a remarkable correlation between g-synuclein and
leptin mRNA levels in human WAT samples and following
PPARg agonist treatment of mature 3T3-L1 adipocytes; this
suggests that g-synuclein shares gene promoter elements with
leptin. Leptin expression is induced by insulin (45–48) via
stimulation of glucose utilization (49–51) and expression is
typically correlated with fat cell size/adiposity, but the inﬂuence
of these metabolic and hormonal factors on g-synuclein expres-
sionremaintobedetermined.Recently,usinglarge-scaleanalysis
of protein-protein interactions in human embyronic kidney 293
cells, Ewing et al. (52) found that g-synuclein protein binds fatty
acidbindingprotein4andhepatocytenuclearfactor4,important
proteins regulating fat and glucose metabolism. g-Synuclein also
bound tissue inhibitor of metalloproteinase-2 (52), a protein
recently found to be increased ;2-fold in the SC WAT of obese
FIGURE 6 Adipose g-synuclein transcript levels are increased in
human obesity and highest in SC fat of adult women. (A) g-Synuclein
mRNA abundance in SC WAT samples derived from a cohort of adult
women (9 nonobese, 21 obese; different from those depicted in Fig.
4) confirmed that g-synuclein mRNA expression is increased in
obesity, qualitatively similar to results observed for leptin. Values are
means 6 SEM. **Obese and nonobese differ, P,0.001. (B)
g-Synuclein mRNA levels in a matched set of WAT from the obese
subjects in A were higher in SC WAT than in VAT, similar to leptin
transcript abundance. Values are means 6 SEM, n ¼ 20 matched
sample pairs. Asterisks indicate that SC and VAT differ: **P ,
0.001;***P , 0.0001.
846 Oort et al.humans (53). Although these associations are interesting, it
remains to be seen if g-synuclein interacts with these proteins in
adipocytes and whether such protein-protein interactions inﬂu-
ence metabolism or adiposity.
Insummary,ourresultsareconsistentwiththehypothesisthat
g-synuclein is a PPARg-regulated gene with an important role in
fat cell physiology. The functional relevance of robust coex-
pression of select proteins such as Tusc5 and g-synuclein in adi-
pocytes and peripheral neurons remains mysterious. Neurons,
like adipocytes, display morphologic and functional plasticity
andbothcelltypesaresensitivetochangesinmetabolicstatusand
insulin action. Compromised PNS function in obesity, prediabe-
tes, and type 2 diabetes is an early event related to system-wide
metabolic dysregulation and, intriguingly, TZD seem to improve
diabetes-associated PNS functional indices (54), which may be
independentofchangesinbloodglucosestatus.Becauseprevious
phenotyping experiments in g-synuclein knockout mice focused
on neurophysiology and neuroanatomical outcomes (13), it
would be interesting to extend these efforts to focus on metab-
olism and adiposity phenotypes to help clarify the physiological
roles of this protein in adipose tissue.
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